Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician

Perifollicular Xanthomas Associated with Epidermal Growth Factor Receptor Inhibitor Therapy

(2010) T Eames et al.   ACTA DERMATO-VENEREOLOGICA

Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life

(2010) Smita S. Joshi et al.   CANCER

Hautreaktionen unter EGFR-Inhibitoren – Klinik und Management

(2010) A Wollenberg et al.   DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

(2010) Mario E. Lacouture et al.   JOURNAL OF CLINICAL ONCOLOGY

Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines

(2009) S.S. Han et al.   BRITISH JOURNAL OF DERMATOLOGY

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity andKRASstatus in patients receiving panitumumab monotherapy

(2009) Marc Peeters et al.   CANCER

MANAGEMENT OF SKIN RASH DURING EGFR-TARGETED MONOCLONAL ANTIBODY TREATMENT FOR GASTRO INTESTINAL MALIGNANCIES: CANADIAN RECOMMENDATIONS

(2009) Barb Melosky et al.   Current Oncology

New drug therapies and their effect on the skin

(2009) Regina Treudler   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption

(2009) Alon Scope et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia

(2009) T Eames et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Skin toxicities associated with epidermal growth factor receptor inhibitors

(2009) Tianhong Li et al.   Targeted Oncology

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes

(2008) Aminah Jatoi et al.   CANCER

A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition

(2008) Andreas Wollenberg et al.   EXPERIMENTAL DERMATOLOGY

Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting

(2007) C. Gridelli et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY